Evidence map›Paper›PMID 27167970›Full record

ArticleJournal of neurochemistry2016

FABP-1 gene ablation impacts brain endocannabinoid system in male mice.

Gregory G Martin, Sarah Chung, Danilo Landrock, Kerstin K Landrock, Huan Huang, Lawrence J Dangott, Xiaoxue Peng, Martin Kaczocha, Drew R Seeger, Eric J Murphy and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of neurochemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
6.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Mechanisms of endocannabinoid transport in the brain.British journal of pharmacology · 2022
    Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. ΔJournal of lipid research · 2018
    Article
  11. Article
  12. FABP1 knockdown in human enterocytes impairs proliferation and alters lipid metabolism.Biochimica et biophysica acta. Molecular and cell biology of lipids · 2017
    Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Gregory G MartinDepartment of Physiology and Pharmacology, Texas A&M University, College Station, Texas, USA.ORCID 0000-0002-0092-4612
Sarah ChungDepartment of Physiology and Pharmacology, Texas A&M University, College Station, Texas, USA.
Danilo LandrockDepartment of Pathobiology, Texas A&M University, College Station, Texas, USA.
Kerstin K LandrockDepartment of Pathobiology, Texas A&M University, College Station, Texas, USA.
Huan HuangDepartment of Physiology and Pharmacology, Texas A&M University, College Station, Texas, USA.
Lawrence J DangottDepartment of Biochemistry and Biophysics, Texas A&M University, College Station, Texas, USA.
Xiaoxue PengDepartment of Anesthesiology, Stony Brook University, Stony Brook, New York, USA.
Martin KaczochaDepartment of Anesthesiology, Stony Brook University, Stony Brook, New York, USA.
Drew R SeegerDepartment of Biomedical Sciences, School of Medicine and Health Sciences, University of North Dakota, Grand Forks, North Dakota, USA.
Eric J MurphyDepartment of Biomedical Sciences, School of Medicine and Health Sciences, University of North Dakota, Grand Forks, North Dakota, USA.
Mikhail Y GolovkoDepartment of Biomedical Sciences, School of Medicine and Health Sciences, University of North Dakota, Grand Forks, North Dakota, USA.
Ann B KierDepartment of Pathobiology, Texas A&M University, College Station, Texas, USA.
Friedhelm SchroederDepartment of Physiology and Pharmacology, Texas A&M University, College Station, Texas, USA.
Texas A&M University · USUniversity of North Dakota · USStony Brook University · US

Funding

Pilot Projects CoreP30GM103329 · NIGMS · UNIVERSITY OF NORTH DAKOTA · PI GEIGER, JONATHAN DAVID · 2012 to 2016
$5.1M
Anandamide Transport InhibitorsR01DA035923 · NIDA · STATE UNIVERSITY NEW YORK STONY BROOK · PI KACZOCHA, MARTIN · 2013 to 2017
$3.8M
FABPs: Novel Roles in Pain and InflammationR01DA035949 · NIDA · STATE UNIVERSITY NEW YORK STONY BROOK · PI KACZOCHA, MARTIN · 2014 to 2022
$3.0M
Veterinary Student Research TrainingT35OD010991 · OD · TEXAS A&M AGRILIFE RESEARCH · PI GADDY, DANA · 2012 to 2025
$920k
Research Education Program for Laboratory Animal Medicine VeterinariansR25OD016574 · OD · TEXAS A&M UNIVERSITY · PI KIER, ANN B. · 2013 to 2016
$578k
NIDA NIH HHS R01 DA035923NIDA NIH HHS R01 DA035949NIGMS NIH HHS P30 GM103329NIH HHS R25 OD016574NIH HHS T35 OD010991
6 · The paper itself

Abstract

Liver fatty acid-binding protein (FABP1, L-FABP) has high affinity for and enhances uptake of arachidonic acid (ARA, C20:4, n-6) which, when esterified to phospholipids, is the requisite precursor for synthesis of endocannabinoids (EC) such as arachidonoylethanolamide (AEA) and 2-arachidonoylglycerol (2-AG). The brain derives most of its ARA from plasma, taking up ARA and transporting it intracellularly via cytosolic fatty acid-binding proteins (FABPs 3,5, and 7) localized within the brain. In contrast, the much more prevalent cytosolic FABP1 is not detectable in the brain but is instead highly expressed in the liver. Therefore, the possibility that FABP1 outside the central nervous system may regulate brain AEA and 2-AG was examined in wild-type (WT) and FABP1 null (LKO) male mice. LKO increased brain levels of AA-containing EC (AEA, 2-AG), correlating with increased free and total ARA in brain and serum. LKO also increased brain levels of non-ARA that contain potentiating endocannabinoids (EC*) such as oleoyl ethanolamide (OEA), PEA, 2-OG, and 2-PG. Concomitantly, LKO decreased serum total ARA-containing EC, but not non-ARA endocannabinoids. LKO did not elicit these changes in the brain EC and EC* as a result of compensatory up-regulation of brain protein levels of enzymes in EC synthesis (NAPEPLD, DAGLα) or cytosolic EC chaperone proteins (FABPs 3, 5, 7, SCP-2, HSP70), or cannabinoid receptors (CB1, TRVP1). These data show for the first time that the non-CNS fatty acid-binding protein FABP1 markedly affected brain levels of both ARA-containing endocannabinoids (AEA, 2-AG) as well as their non-ARA potentiating endocannabinoids. Fatty acid-binding protein-1 (FABP-1) is not detectable in brain but instead is highly expressed in liver. The possibility that FABP1 outside the central nervous system may regulate brain endocannabinoids arachidonoylethanolamide (AEA) and 2-arachidonoylglycerol (2-AG) was examined in wild-type (WT) and FABP-1 null (LKO) male mice. LKO increased brain levels of arachidonic acid-containing endocannabinoids (AEA, 2-AG), correlating with increased free and total arachidonic acid in brain and serum. Read the Editorial Highlight for this article on page 371.

Indexed as

AnimalsArachidonic AcidsBrainEndocannabinoidsFatty Acid-Binding ProteinsGlyceridesLiverMaleMice, Inbred C57BLMice, KnockoutOleic AcidsPolyunsaturated AlkamidesanandamideArachidonic AcidsEndocannabinoidsFabp1 protein, mouseFatty Acid-Binding ProteinsGlyceridesOleic AcidsoleoylethanolamidePolyunsaturated Alkamidesbrainendocannabinoidgene ablationliver fatty acid-binding proteinmouse

Identifiers

PMID27167970
PMCPMC4961623
OpenAlexW2391002875

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.